Review



waveform analysis software flex pro7.0  (Weisang GmbH)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Weisang GmbH waveform analysis software flex pro7.0
    Waveform Analysis Software Flex Pro7.0, supplied by Weisang GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/waveform+analysis+software/waveform+analysis+software+flex+pro7+0/pm32028775-64-5-10
    Average 90 stars, based on 1 article reviews
    waveform analysis software flex pro7.0 - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    Software:

    Article Title: Reproducibility of pulmonary blood flow measurements by phase-contrast MRI using different 1.5 T MR scanners at two institutions
    Article Snippet: .. The AT, AV, M, and M/AV were calculated by waveform analysis software (Flex Pro7.0, WEISANG, Ingbert, Germany). ..

    Article Title: Pulmonary flow assessment by phase-contrast MRI can predict short-term mortality of fibrosing interstitial lung diseases.
    Article Snippet: Background: Phase-contrast magnetic resonance imaging (PC-MRI) can determine pulmonary hemodynamics noninvasively.. Pulmonary hypertension causes changes in pulmonary hemodynamics and is a factor for acute exacerbation and death in interstitial lung diseases (ILD).. Purpose: To determine associations between pulmonary hemodynamics measured by PC-MRI and short-term mortality in patients with ILD.



    Similar Products

    waveform analysis software mvp-rf8-s  (MicroStone Corporation)
    90
    MicroStone Corporation waveform analysis software mvp-rf8-s
    Waveform Analysis Software Mvp Rf8 S, supplied by MicroStone Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/waveform+analysis+software/inertial+sensor+mvp+rf8+bc/pm38599366-61-19-23
    Average 90 stars, based on 1 article reviews
    waveform analysis software mvp-rf8-s - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    waveform analysis software  (Hamamatsu)
    90
    Hamamatsu waveform analysis software
    Waveform Analysis Software, supplied by Hamamatsu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/waveform+analysis+software/waveform+analysis+software/pmc11143964-271-6-10
    Average 90 stars, based on 1 article reviews
    waveform analysis software - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    waveform analysis of cardiomyocyte software  (Hamamatsu)
    90
    Hamamatsu waveform analysis of cardiomyocyte software
    Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
    Waveform Analysis Of Cardiomyocyte Software, supplied by Hamamatsu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/waveform+analysis+software/waveform+analysis+of+cardiomyocyte+software/pmc08369502-188-8-11
    Average 90 stars, based on 1 article reviews
    waveform analysis of cardiomyocyte software - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    arterial waveform analysis software with a validated generalized transfer function  (AtCor Medical)
    90
    AtCor Medical arterial waveform analysis software with a validated generalized transfer function
    Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
    Arterial Waveform Analysis Software With A Validated Generalized Transfer Function, supplied by AtCor Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/waveform+analysis+software/arterial+waveform+analysis+software/pmc08385571-83-9-12
    Average 90 stars, based on 1 article reviews
    arterial waveform analysis software with a validated generalized transfer function - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    waveform analysis of cardiomyocyte software ver.1.2.1j  (Hamamatsu)
    90
    Hamamatsu waveform analysis of cardiomyocyte software ver.1.2.1j
    Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
    Waveform Analysis Of Cardiomyocyte Software Ver.1.2.1j, supplied by Hamamatsu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/waveform+analysis+software/video+capture+library+for+labview++ver+1+0++plug+in/pm34413773-242-18-24
    Average 90 stars, based on 1 article reviews
    waveform analysis of cardiomyocyte software ver.1.2.1j - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    waveform analysis software igor pro 8.03  (wavemetrics inc)
    90
    wavemetrics inc waveform analysis software igor pro 8.03
    Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
    Waveform Analysis Software Igor Pro 8.03, supplied by wavemetrics inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/waveform+analysis+software/igor+pro+8/pmc07920032-84-5-11
    Average 90 stars, based on 1 article reviews
    waveform analysis software igor pro 8.03 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    waveform analysis software acqknowledge  (BIOPAC)
    90
    BIOPAC waveform analysis software acqknowledge
    Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
    Waveform Analysis Software Acqknowledge, supplied by BIOPAC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/waveform+analysis+software/waveform+data+acquisition+analysis+software+acqknowledge/pmc07858273-51-14-18
    Average 90 stars, based on 1 article reviews
    waveform analysis software acqknowledge - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    fdss waveform analysis software  (Hamamatsu)
    90
    Hamamatsu fdss waveform analysis software
    Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
    Fdss Waveform Analysis Software, supplied by Hamamatsu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/waveform+analysis+software/fdss+waveform+analysis+software/pmc07840483-97-14-18
    Average 90 stars, based on 1 article reviews
    fdss waveform analysis software - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    waveform analysis software flex pro7.0  (Weisang GmbH)
    90
    Weisang GmbH waveform analysis software flex pro7.0
    Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
    Waveform Analysis Software Flex Pro7.0, supplied by Weisang GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/waveform+analysis+software/waveform+analysis+software+flex+pro7+0/pm32028775-64-5-10
    Average 90 stars, based on 1 article reviews
    waveform analysis software flex pro7.0 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    waveform analysis software chart 5  (ADInstruments)
    90
    ADInstruments waveform analysis software chart 5
    Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
    Waveform Analysis Software Chart 5, supplied by ADInstruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/waveform+analysis+software/signal+processing+software+chart+4+2+3/pmc07331419-68-9-3
    Average 90 stars, based on 1 article reviews
    waveform analysis software chart 5 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.

    Journal: Frontiers in Pharmacology

    Article Title: High-Throughput Drug Screening System Based on Human Induced Pluripotent Stem Cell-Derived Atrial Myocytes ∼ A Novel Platform to Detect Cardiac Toxicity for Atrial Arrhythmias

    doi: 10.3389/fphar.2021.680618

    Figure Lengend Snippet: Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.

    Article Snippet: Recording data were analyzed using Waveform Analysis of Cardiomyocyte Software (Ver.1.2.1J, Hamamatsu Photonics K.K.).

    Techniques: Immunostaining, Control, Immunofluorescence, Expressing, Comparison